RxDoctor Payments Data

Emily Levitt-Gopie

Family · Ewa Beach, HINPI 1992006217

Payments from drug & device makers

$1,793in general payments, 2019–2025

Across 38 payments — averaging $47.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$565
  • Gilead$539
  • Lilly USA, LLC$145
  • EMD Serono, Inc.$125
  • Axsome Therapeutics, Inc.$109
  • AbbVie$105
  • plus $205 from 6 others

What the payments were for

  • Food & beverage$1,793100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,793 in reported general payments places this provider in the 80th percentile of 466 family providers in Hawaii.

See all family providers in Hawaii

Medicare billing

Part B allowed, 2024
$2,091
Medicare patients
20
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$80,537
TrulicityDulaglutide24$33,839
MounjaroTirzepatide16$33,837
JardianceEmpagliflozin34$33,015
DescovyEmtricitabine/Tenofov Alafenam12$27,959
Isentress HdRaltegravir Potassium12$25,354
Synjardy XrEmpagliflozin/Metformin Hcl20$22,734
Etravirine11$12,212
Breo ElliptaFluticasone/Vilanterol12$10,736
Atorvastatin Calcium170$2,859
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,046
Albuterol Sulfate HfaAlbuterol Sulfate67$1,960
Losartan Potassium113$1,917
Nano 2nd Gen Pen NeedlePen Needle, Diabetic21$1,844
Rosuvastatin Calcium76$1,833

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$42$80,53757 claims
Lilly USA, LLCTrulicity, Mounjaro$145$67,67640 claims
Boehringer IngelheimJardiance, Synjardy Xr$28$55,74854 claims
GileadDescovy$539$27,95912 claims
GSKBreo Ellipta$49$10,73612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 466 family providers in Hawaii.

Other family in Ewa Beach

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →